s6y

Lakewood-Amedex Biotherapeutics Inc.

Ticker
LABT
CIK
2079272
Industry
Pharmaceutical Preparations

Financials 3

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026

News 6

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing

Ownership 6

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities

Prospectus 19

  1. S-1 General form of registration statement for all companies including face-amount certificate companies
  2. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 19 prospectus filings

Proxies 3

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 10

  1. EFFECT Notice of Effectiveness
  2. SCHEDULE 13G
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. UPLOAD Letter (PDF)
  8. CERT Certification by an exchange approving securities for listing
  9. EFFECT Notice of Effectiveness
  10. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)